Omeros Corporation’s (OMER) Hold Rating Reaffirmed at Cantor Fitzgerald
Several other brokerages have also recently issued reports on OMER. Cowen and Company reaffirmed an outperform rating on shares of Omeros Corporation in a research note on Saturday, June 3rd. Maxim Group reaffirmed a buy rating and set a $24.00 price objective (up previously from $23.00) on shares of Omeros Corporation in a research note on Tuesday, August 8th. BidaskClub cut shares of Omeros Corporation from a buy rating to a hold rating in a research note on Wednesday, June 28th. Wedbush reaffirmed an outperform rating and set a $47.00 price objective on shares of Omeros Corporation in a research note on Wednesday, May 10th. Finally, WBB Securities reaffirmed a strong-buy rating and set a $75.00 price objective on shares of Omeros Corporation in a research note on Wednesday, June 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Omeros Corporation presently has a consensus rating of Buy and a consensus target price of $32.80.
Omeros Corporation (OMER) traded down 3.74% during trading on Thursday, reaching $20.05. The company had a trading volume of 852,868 shares. The firm’s market capitalization is $898.30 million. Omeros Corporation has a one year low of $7.20 and a one year high of $27.09. The firm’s 50-day moving average price is $21.58 and its 200 day moving average price is $16.97.
Omeros Corporation (NASDAQ:OMER) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.12. The business had revenue of $17.15 million for the quarter, compared to analysts’ expectations of $14.63 million. During the same period in the prior year, the company posted ($0.32) EPS. The firm’s revenue was up 71.5% on a year-over-year basis. Equities analysts forecast that Omeros Corporation will post ($1.30) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Omeros Corporation’s (OMER) Hold Rating Reaffirmed at Cantor Fitzgerald” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/25/omeros-corporations-omer-hold-rating-reaffirmed-at-cantor-fitzgerald.html.
In other news, VP Michael A. Jacobsen sold 12,000 shares of the company’s stock in a transaction that occurred on Friday, June 16th. The shares were sold at an average price of $24.95, for a total value of $299,400.00. Following the transaction, the vice president now directly owns 19,500 shares in the company, valued at approximately $486,525. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Michael A. Jacobsen sold 24,000 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $21.20, for a total transaction of $508,800.00. Following the completion of the transaction, the vice president now owns 2,650 shares in the company, valued at $56,180. The disclosure for this sale can be found here. Corporate insiders own 13.60% of the company’s stock.
Several institutional investors have recently modified their holdings of OMER. Ingalls & Snyder LLC raised its position in shares of Omeros Corporation by 1.0% in the second quarter. Ingalls & Snyder LLC now owns 5,143,289 shares of the biopharmaceutical company’s stock valued at $102,377,000 after buying an additional 50,970 shares in the last quarter. Vanguard Group Inc. raised its stake in Omeros Corporation by 5.4% in the second quarter. Vanguard Group Inc. now owns 1,825,671 shares of the biopharmaceutical company’s stock worth $36,341,000 after buying an additional 94,280 shares during the period. State Street Corp raised its stake in Omeros Corporation by 7.3% in the second quarter. State Street Corp now owns 987,057 shares of the biopharmaceutical company’s stock worth $19,652,000 after buying an additional 66,827 shares during the period. Northern Trust Corp raised its stake in Omeros Corporation by 6.4% in the second quarter. Northern Trust Corp now owns 572,576 shares of the biopharmaceutical company’s stock worth $11,397,000 after buying an additional 34,328 shares during the period. Finally, UBS Group AG raised its stake in Omeros Corporation by 4.2% in the first quarter. UBS Group AG now owns 398,356 shares of the biopharmaceutical company’s stock worth $6,023,000 after buying an additional 16,075 shares during the period. Hedge funds and other institutional investors own 43.94% of the company’s stock.
About Omeros Corporation
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.